NCT06868836View on ClinicalTrials.gov

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

April 30, 2027

Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
DRUG

JS207

JS207 (10 mg/kg or 15 mg/kg, IV, d1)

DRUG

Pemetrexed

Pemetrexed (500 mg/m², IV, d1)

DRUG

Carboplatin or cisplatin

Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles

Trial Locations (1)

510080

RECRUITING

Guangdong Provicial People's Hospital, Guangzhou

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT06868836 - A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter